BackgroundThis study evaluates spike protein IgG antibody response following Oxford-AstraZeneca COVID-19 vaccination using the AbC-19™ lateral flow device.MethodsPlasma samples were collected from n = 111 individuals from Northern Ireland. The majority were >50 years old and/or clinically vulnerable. Samples were taken at five timepoints from pre-vaccination until 6-months post-first dose.Results20.3% of participants had detectable IgG responses pre-vaccination, indicating prior COVID-19. Antibodies were detected in 86.9% of participants three weeks after the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% three weeks post-second vaccine. At 6-months post-first dose, this decreased to 90.5%. At all timepoints, previously infected participants had significantly higher antibody levels than those not previously infected.ConclusionThis study demonstrates that strong anti-spike protein antibody responses are evoked in almost all individuals that receive two doses of Oxford-AstraZeneca vaccine, and which largely persist beyond six months after first vaccination.
|Number of pages||5|
|Early online date||3 Mar 2022|
|Publication status||Published (in print/issue) - 20 Apr 2022|
Bibliographical noteFunding Information:
The study was funded by Abingdon Health, United Kingdom who also provided the AbC-19™ testing devices. Abingdon Health had no other involvement in the study.
© 2022 The Authors
- Adenovirus vector-based vaccine
- Antibody response
- COVID-19 vaccination
- Oxford-AstraZeneca ChAdOx1